1.
Article
in English
| IMSEAR
| ID: sea-95546
ABSTRACT
Indinavir is a protease inhibitor used in the treatment of HIV infected individuals and as post-exposure prophylaxis. Indinavir is associated with various adverse effects including gastrointestinal, a lipodystrophy syndrome and nephrolithiasis. We describe indirect hyperbilirubinemia as an adverse effect of indinavir in a person on post-exposure prophylaxis (PEP).
Subject(s)
Adult , Dose-Response Relationship, Drug , Drug Therapy, Combination , Female , HIV Infections/prevention & control , HIV Protease Inhibitors/adverse effects , Humans , Hyperbilirubinemia/chemically induced , India , Indinavir/adverse effects , Lamivudine/therapeutic use , Liver Function Tests , Prognosis , Risk Assessment , Severity of Illness Index , Zidovudine/therapeutic use
2.
Indian J Lepr
;
1992 Jul-Sep; 64(3): 381-4
Article
in English
| IMSEAR
| ID: sea-54777